Arcturus has two proprietary technologies that have the potential to solve the major hurdles in RNA medicine development. Our Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR™) delivery platform and our unlocked nucleomonomer agent (UNA) Oligomer technology can be used together or separately to create the next-generation of safe, effective RNA medicines.
LUNAR allows systemic delivery of all types of RNA therapeutics to target tissues. UNA oligomers are more stable, more potent and less toxic than standard oligomers.
We use our technologies in house, and partner with industry leaders, to discover and develop RNA medicines that treat rare and orphan diseases.
October 19, 2017
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines
October 6, 2017
Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference
September 27, 2017
Webcast: Arcturus Merger w/Alcobra Conference Call